{
    "organizations": [],
    "uuid": "44ee15cd3c7467655c7fdc9198c73f0f0dcb8572",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vertex-pharmaceuticals-inc-reports/brief-vertex-pharmaceuticals-inc-reports-qtrly-eps-of-0-81-idUSASC09XUW",
    "ord_in_thread": 0,
    "title": "Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS\n* QTRLY ADJUSTED EARNINGS PER SHARE $0.76 * QTRLY TOTAL REVENUES $640.8 MILLION VERSUS $714.7 MILLION\n* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION\n* Q1 EARNINGS PER SHARE VIEW $0.63, REVENUE VIEW $622.7 MILLION â€” THOMSON REUTERS I/B/E/S Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-27T04:31:00.000+03:00",
    "crawled": "2018-04-27T17:15:41.034+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "report",
        "financial",
        "result",
        "qtrly",
        "adjusted",
        "earnings",
        "per",
        "share",
        "qtrly",
        "total",
        "revenue",
        "million",
        "versus",
        "million",
        "company",
        "reiterates",
        "total",
        "cf",
        "product",
        "revenue",
        "guidance",
        "billion",
        "billion",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon"
    ]
}